This report identifies the global eye infections treatment market size in for the year 2014-2016, and forecast of the same for year 2021. It also highlights the potential growth opportunities in the coming years, while also reviewing the market drivers, restraints, growth indicators, challenges, market dynamics, competitive landscape, and other key aspects with respect to global eye infections treatment market.
Geographically Asia dominated global eye infections treatment market, and is projected to have fastest growth, owing to rapidly increasing aging population, warm climatic condition and modernizing healthcare infrastructure in this region. Among all the category of eye infection, conjunctivitis has the highest market share in global eye infections treatment market.
This report segments global eye infections treatment market on the basis of category, cause of infection, drug type, end-user, and regional market as follows:
Eye Infections Treatment Market, By Category: Conjunctivitis, Blepharitis, Keratitis, Vitritis, Chorioretinitis and Neuroretinitis
Eye Infections Treatment Market, By Cause of Infection: Bacteria, Viruses, Irritants and Allergies
Eye Infections Treatment Market, By Drug Type: Corticosteroids, Quinolone Antibiotics, Macrolide Antibiotics, Tetracycline Antibiotics, Polyene Antifungals, Aminoglycoside Antibiotic / Polypeptide Antibiotic / Corticosteroid Combinations, Aminoglycoside Antibiotics, Sulfa Antibiotics and Others
This report has been further segmented into major regions, which includes detailed analysis of each region such as: North America, Europe, Asia-Pacific (APAC) and Rest of the World (RoW) covering all the major country level markets in each of the region
This report identifies all the major companies operating in the eye infections treatment market. Some of the major companies’ profiles in detail are as follows:
Roche Holding AG
GlaxoSmithKline Pharmaceuticals Ltd
Valeant Pharmaceuticals International, Inc.
Novartis International AG
Santen Pharmaceutical Co., Ltd.
Please Note: The report is to be delivered in 1-2 working days after an order is placed.
2. Executive Summary
3. Market Landscape
3.1. Market Share Analysis
3.2. Comparative Analysis
3.3. Product Benchmarking
3.4. End User Profiling
3.5. Top 5 Financials Analysis
4. Eye Infections Treatment Market– Market Forces
4.1.1. Availability of new and more efficient drugs such as eye drop or eye ointment
4.1.2. Change in population demographics
4.1.3. Increasing frequency of blindness amongst the geriatric population
4.2.1. The research and development, and testing having higher cost
4.2.2. Stringent government regulations
4.3.1. Countries with warm climatic conditions
4.3.2. Increase in adoption of eye infections treatment drugs
4.5. Porter’s Five Forces Analysis
4.5.1. Bargaining Power of Suppliers
4.5.2. Bargaining Power of Buyers
4.5.3. Threat of New Entrants
4.5.4. Threat of Substitutes
4.5.5. Degree of Competition
5. Eye Infections Treatment Market, By Category
6. Eye Infections Treatment Market, By Cause of Infection
7. Eye Infections Treatment Market, By Drug Type
7.2. Quinolone Antibiotics
7.3. Macrolide Antibiotics
7.4. Tetracycline Antibiotics
7.5. Polyene Antifungals
7.6. Aminoglycoside Antibiotic / Polypeptide Antibiotic / Corticosteroid Combinations
7.7. Aminoglycoside Antibiotics
7.8. Sulfa Antibiotics
8. Eye Infections Treatment Market, By Geography
8.1.7. Rest of Europe
8.2. Asia Pacific
8.2.4. South Korea
8.2.5. Rest of Asia-Pacific
8.3. North America
8.4. Rest of the World (RoW)
8.4.2. Rest of RoW
9. Eye Infections Treatment – Market Entropy
9.2. Technological Developments
9.3. Merger & Acquisitions, and Joint Ventures
9.4. Supply- Contract
10. Company Profiles (Introduction, Financials, Key Insights, Key Strategy, Product Portfolio, SWOT Analysis)
10.1. Roche Holding AG
10.2. GlaxoSmithKline Pharmaceuticals Ltd
10.3. Valeant Pharmaceuticals International, Inc.
10.4. Novartis International AG
10.5. Santen Pharmaceutical Co., Ltd.
10.6. Pfizer Inc.
10.7. Valeant Pharmaceuticals International, Inc.
10.8. Merck & Co.
10.9. Allergan, Plc
10.10. Bayer AG
*More than 40 Companies are profiled in this Research Report, Complete List available on Request*
"*Financials would be provided on a best efforts basis for private companies"
11.3. Research Methodology
11.4. Expert Insights